ESMO GI 2024

Gastric and Oesophageal Cancer

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Cancers of the Colon, Rectum, and Anus

Post-operative MRD status more prognostic than TNM stage

Presented By

Dr Arvind Dasari, MD Anderson Cancer Center, TX, USA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:48

CAPRI 2 GOIM trial navigates biomarker-driven therapy

Presented By

Dr Giulia Martini, University of Campania Luigi Vanvitelli, Italy

Trial

Phase 2, CAPRI 2 GOIM

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:44

Meta-analysis of triplet therapy in BRAFV600E-mutated mCRC

Presented By

Dr Davi Said G. Celso, Federal University of Viçosa, Brazil

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:41

CheckMate 8HW: Nivolumab/ipilimumab in MSI-H/dMMR mCRC

Presented By

Dr Sara Lonardi, Veneto Institute of Oncology, Italy

Trial

Phase 3, CheckMate 8HW

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

Sequence effect for third-line treatment of mCRC

Presented By

Prof. Michel Ducreux, Gustave Roussy, France

Trial

Phase 2, SOREGATT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:36

REGINA meets stage 1 endpoint in rectal cancer and moves to stage 2 with reduced dose regorafenib

Presented By

Dr Francesco Sclafani, Institut Jules Bordet, Belgium

Trial

Phase 2, REGINA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:34

High efficacy of pembrolizumab combined with standard therapy in patients with MSS/pMMR mCRC and high immune infiltrate

Presented By

Prof. David Tougeron, Poitiers University Hospital, France

Trial

Phase 2, POCHI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:31

Prognostic value of ctDNA in stage III colon cancer

Presented By

Prof. Julien Taieb, Paris Descartes University, France

Trial

Phase 3, IDEA-France, IDEA-Greece

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:28

Neoadjuvant combined immunotherapy also effective in MSS/pMRR CRC

Presented By

Dr Mehraneh Jafari, Weill Cornell Medical Center, NY, USA

Trial

Phase 2, NEST-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:25

Neoadjuvant immunotherapy plus radiation effective in advanced MSI-H rectal cancer

Trial

Phase 2, ECOG-ACRIN EA2201

Type

Peer-reviewed article

21 August 2024 11:19

General GI Cancer

Peri- or post-operative chemotherapy benefits patients with resectable CRCLM

Presented By

Dr Giacomo Bregni, Brussels University Hospital, Belgium

Trial

Phase 3

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:12

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

TRANSMET meets OS endpoint

Presented By

Dr Maximiliano Gelli, Gustave Roussy, France

Trial

TRANSMET

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:05